A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Inclusion Criteria: * Subject's body weight is ≥50 kg and BMI is within the range of 18 to 32 * Subject is a healthy volunteer. * Subject's PT, aPTT, and TT are within the normal laboratory range. * Subject is a nonsmoker Exclusion Criteria: * Subject has a current or recent history of regular alcohol consumption. * Subjects who are enrolled in Part B and allergic to acetylsalicylic acid, other salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or dabigatran. * Part B Cohort 2 only: subjects who are poor metabolizers of clopidogrel (CYP2C19\*2/\*2, \*2/\*3, or \*3/\*3 genotype) * Subject has a presence or history of coagulation abnormality. * Subjects need to receive a surgery or clinical procedures associated with high bleeding risk. * Subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding, gingival bleeding. * Subject has a history of peptic ulcer or gastrointestinal bleeding.